SCHEMBL4959481

SCHEMBL4959481

[2H]C(CCC[C@H]1[C@H]2NC(=O)N[C@H]2C[S+]1[O-])C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.43
ABL1 P00519 2/20 0.43
IDE P14735 2/20 0.43
RIN1 Q13671 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HLCS P50747 6/20 0.34
PPARG P37231 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18924547 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL29598 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL30508570 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL14562968 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL17752940 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL10171650 0.88 TDP1 (0.56) TDP1ABL1IDERIN1MEN1
SCHEMBL17761083 0.82 TDP1 (0.45) TDP1ABL1IDERIN1MEN1
SCHEMBL21488894 0.78 TDP1 (0.58) TDP1ABL1IDERIN1MEN1
SCHEMBL21516801 0.78 TDP1 (0.58) TDP1ABL1IDERIN1MEN1
SCHEMBL21517145 0.78 TDP1 (0.58) TDP1ABL1IDERIN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8849577-B2 Methods of identifying biochemical pathways METABOLON, INC. (US) 2014-09-30 US disclosed
US-20080161228-A1 Using metabolomics to expedite drug discovery and development; invention provides means to select and advance most selective lead compounds from series of candidates based on metabolomic profiles which contain data regarding both expected or intended (e.g., on-target) and unexpected effects of compounds METABOLON INC. (US) 2008-07-03 US disclosed